NCT01804361View on ClinicalTrials.gov

Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Dry Eye Syndromes
Interventions
DRUG

Haporine-S

1 or 2 drops twice a day at 12 hour interval for 12 weeks

DRUG

Restasis (cyclosporine 0.05%)

1 or 2 drops twice a day at 12 hour interval for 12 weeks

Trial Locations (6)

602-739

Busan National University Hospital, Busan

110-744

Seoul National University Hospital, Seoul

135-720

Yonsei University Gangnam Severance Hospital, Seoul

136-705

Korea University Anam Hospital, Seoul

138-736

Asan Medical Center, Seoul

152-703

Korea University Guro Hospital, Seoul

All Listed Sponsors
collaborator

BTO Pharm. Co., Ltd.

INDUSTRY

lead

DH Bio Co., Ltd.

INDUSTRY

NCT01804361 - Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes | Biotech Hunter | Biotech Hunter